• Home
  • Latest
  • Coins2Day 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
TechElizabeth Holmes

What people are saying about Theranos founder Elizabeth Holmes’ fraud conviction

By
Jonathan Vanian
Jonathan Vanian
Down Arrow Button Icon
By
Jonathan Vanian
Jonathan Vanian
Down Arrow Button Icon
January 3, 2022, 9:44 PM ET

Theranos founder Elizabeth Holmes was convicted of criminal fraud on Monday, marking a dramatic fall from grace for the one-time Silicon Valley superstar.  

Holmes was once among the most admired tech CEOs for her blood-testing startup that garnered a $9 billion valuation from investors who believed the company’s technology would revolutionize healthcare. But jurors decided that Holmes was guilty on four counts of fraud and conspiracy, leaving the possibility that she could spend nearly two decades in prison.

Jurors found Holmes not guilty on four other felony charges, and they deadlocked on another three. 

Several high-profile people took to Twitter to comment on the trial’s outcome. 

Journalist John Carreyrou noted on Twitter how Holmes’ four guilty charges were related to defrauding investors rather than patients, who relied on the company’s blood tests even though executives knew they were faulty. Carreyrou’s reporting about Theranos for The Wall Street Journal was instrumental in publicly exposing the startup’s struggles with its blood-testing technology and the extent to which Holmes and fellow executives embellished the technology’s capabilities.

The 4 guilty counts are all investor counts. The investor conspiracy count and the counts relating to the hedge fund PFM, the ex Cravath attorney Mosley and the DeVos family.

— John Carreyrou (@JohnCarreyrou) January 4, 2022

Rasu Shrestha, the enterprise executive vice president and chief strategy and transformation officer for Atrium Health, called attention to the dangers of Theranos misleading people about its health diagnostic chops. 

GUILTY – of 4 charges, including conspiracy to commit fraud against investors

“The way #Theranos is operating is like trying to build a bus while you’re driving the bus. Someone is going to get killed.”

― @JohnCarreyrou, #BadBlood #ElizabethHolmes pic.twitter.com/cyn2w0RPWq

— Rasu Shrestha MD MBA (@RasuShrestha) January 4, 2022

Kyle Edmonds, an assistant professor of medicine and palliative medicine for the University of California at San Diego, complained about the jury failing to convict Holmes on the charges related to defrauding patients.

Https://twitter.com/kpedmonds/status/1478166889343815683

Healthcare attorney Harry Nelson expressed dismay that it took several years for Holmes to eventually be found guilty. 

About time. The fraud at #Theranos was revealed over 5 years ago. Glad to see #ElizabethHolmes finally get what she deserves; just wish it had happened faster.Https://t.co/Asg5iV15Mf

— Harry Nelson (@nelsonh) January 4, 2022

Tanya Ha, the engagement director for Australia’s Science in Public communications firm, compared Holmes’ trial to the conviction of Martin Shkreli, the controversial ‘Pharma Bro’ who was found guilty of investor fraud in 2017.

#ElizabethHolmes verdict brings to mind securities fraud conviction of ‘Pharma Bro’ Martin Shkreli who (among other things) raised the price of antiparasitic drug Daraprim from US$13.50 to $750 per pill.

It’s a system where you can screw over patients, but NOT rich investors. Https://t.co/dldzAOO3de

— Tanya Ha 🌱 (@Ha_Tanya) January 4, 2022

Elizabeth Renieris, the director Notre Dame-IBM Technology Ethics Lab, pointed out that venture capitalist Tim Draper, who had invested in Theranos and then, after news of the company’s misdeeds emerged, accused the media of conspiring against Holmes, is still investing in tech.

#ElizabethHolmes verdict feels like a good time to remember that Tim Draper was as bullish on #Theranos as he is on #Bitcoin and #Web3 https://t.co/UN5TuI6FaP

— Elizabeth M. Renieris (is back to work, ltd on X) (@hackylawyER) January 4, 2022

Never miss a story: Follow your favorite topics and authors to get a personalized email with the journalism that matters most to you.

About the Author
By Jonathan Vanian
LinkedIn iconTwitter icon

Jonathan Vanian is a former Coins2Day reporter. He covered business technology, cybersecurity, artificial intelligence, data privacy, and other topics.

See full bioRight Arrow Button Icon

Latest in Tech

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
North America
'I meant what I said in Davos': Carney says he really is planning a Canada split with the U.S. along with 12 new trade deals
By Rob Gillies and The Associated PressJanuary 28, 2026
3 days ago
placeholder alt text
Politics
The American taxpayer spent nearly half a billion dollars deploying federal troops to U.S. cities in 2025, CBO finds
By Nick LichtenbergJanuary 28, 2026
3 days ago
placeholder alt text
Economy
Right before Trump named Warsh to lead the Fed, Powell seemed to respond to some of his biggest complaints about the central bank
By Jason MaJanuary 30, 2026
16 hours ago
placeholder alt text
AI
Top engineers at Anthropic, OpenAI say AI now writes 100% of their code—with big implications for the future of software development jobs
By Beatrice NolanJanuary 29, 2026
2 days ago
placeholder alt text
Investing
Jerome Powell got a direct question about the U.S. ‘losing credibility’ and the soaring price of gold and silver. He punted
By Eva RoytburgJanuary 29, 2026
2 days ago
placeholder alt text
C-Suite
Coins2Day 500 CEOs are no longer giving employees an A for effort. Now they want proof of impact
By Claire ZillmanJanuary 28, 2026
3 days ago

Latest in Tech

In this handout, the mug shot of Jeffrey Epstein, 2019.
PoliticsJeffrey Epstein
Elon Musk and Jeffrey Epstein emailed each other for years trying to meet up, new Justice Department records show
By Eva Roytburg and Sasha RogelbergJanuary 30, 2026
9 hours ago
Big TechThe Boring Company
After a decade of silence, Elon Musk’s tunneling startup and its reclusive president, are hitting the media circuit
By Jessica MathewsJanuary 30, 2026
12 hours ago
MagazineEducation
The 1966 cover of Coins2Day Magazine welcomed the Information age. Now the AI era beckons
By Indrani SenJanuary 30, 2026
13 hours ago
Gamestop
Big TechGameStop
Five years after the short squeeze, GameStop’s CEO is betting on a ‘genius or totally foolish’ $100 billion-plus acquisition
By Jake AngeloJanuary 30, 2026
14 hours ago
C-SuitePharmaceutical Industry
‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology
By Nick LichtenbergJanuary 30, 2026
15 hours ago
Sam Altman speaking into a mic.
AIOpenAI
A reported OpenAI IPO later this year may test investor tolerance for the AI boom’s cash bonfire
By Beatrice NolanJanuary 30, 2026
17 hours ago